microbeПроблемы особо опасных инфекцийProblems of Particularly Dangerous Infections0370-10692658-719XRussian Research Anti-Plague Institute “Microbe”10.21055/0370-1069-2013-2-54-59microbe-33Research ArticleПАТОГЕНЕЗ, ЛЕЧЕНИЕPATHOGENESIS, TREATMENTИзучение противовирусной активности химически синтезированных соединений в отношении ортопоксвирусов в экспериментах in vitroStudies of Anti-Viral Activity of Chemically Synthesized Compounds against Orthopoxviruses in vitroКабановА. С.KabanovA. S.vector@vector.nsc.ruСергеевАл. А.SergeevAl. A.vector@vector.nsc.ruБулычевЛ. Е.BulychevL. E.vector@vector.nsc.ruБормотовН. И.BormotovN. I.vector@vector.nsc.ruШишкинаЛ. Н.ShishkinaL. N.vector@vector.nsc.ruСергеевАр. А.SergeevAr. A.vector@vector.nsc.ruБодневС. А.BodnevS. A.vector@vector.nsc.ruСкарновичМ. О.SkarnovichM. O.vector@vector.nsc.ruШевцовА. Р.ShevtsovA. R.vector@vector.nsc.ruСеливановБ. А.SelivanovB. A.seliboba@nioch.nsc.ruТихоновА. Я.TikhonovA. Ya.noemail@neicon.ruАгафоновА. П.AgafonovA. P.vector@vector.nsc.ruСергеевА. Н.SergeevA. N.vector@vector.nsc.ruГосударственный научный центр вирусологии и биотехнологии «Вектор»РоссияState Research Centre of Virology and Biotechnology “Vector”Russian FederationНовосибирский институт органической химии им. Н.Н.Ворожцова СО РАНРоссияNovosibirsk N.N.Vorozhtsov Institute of Organic Chemistry, RAS SBRussian Federation201320062013025459Copyright © Кабанов А.С., Сергеев А.А., Булычев Л.Е., Бормотов Н.И., Шишкина Л.Н., Сергеев А.А., Боднев С.А., Скарнович М.О., Шевцов А.Р., Селиванов Б.А., Тихонов А.Я., Агафонов А.П., Сергеев А.Н., 20132013Кабанов А.С., Сергеев А.А., Булычев Л.Е., Бормотов Н.И., Шишкина Л.Н., Сергеев А.А., Боднев С.А., Скарнович М.О., Шевцов А.Р., Селиванов Б.А., Тихонов А.Я., Агафонов А.П., Сергеев А.Н.Kabanov A.S., Sergeev A.A., Bulychev L.E., Bormotov N.I., Shishkina L.N., Sergeev A.A., Bodnev S.A., Skarnovich M.O., Shevtsov A.R., Selivanov B.A., Tikhonov A.Y., Agafonov A.P., Sergeev A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.microbe.ru/jour/article/view/33

для ST-246 и НИОХ-14 находились в диапазоне от 0,001 до 0,004 мкг/мл, а IS для обоих препаратов были >100000. Кроме того, эффективность химических соединений ST-246 и НИОХ-14 в концентрациях 0,0125; 0,025 и 0,05 мкг/мл в профилактических схемах влияния на инфекционность вируса эктромелии (ВЭ) in vitro была соответственно на 0,6; 3 и 1 lg выше, чем при их внесении через 1 час после заражения ВЭ клеток Vero.

for ST-246 and NIOC-14 is within the range of 0,001-0,004 µg/ml, and IS for both of them is > 100000. In addition, ST-246 and NIOC-14 chemical compound efficacy, concentrated up to 0,0125; 0,025 and 0,05 µg/ml, in accordance with prophylactic charts describing an impact on ectromelia virus (EV) infectivity in vitro, is consequently 0,6; 3 and 1 lg higher than in case of compound application after an hour of Vero cells infection with EV.

ортопоксвирусывирус оспы обезьянвирус натуральной оспыкультура клеток Veroтоксичностьпротивовирусная активностьконденсированные производные пирролидин-25-дионаOrthopoxvirusesMonkeypox virusvariola virusVero cell culturetoxicityanti-viral activitycondensed derivatives of pyrrolidine-25-dionReferencesЗакс Л. Статистическое оценивание. М.: Статистика. 1976. 598 с.Zaks L. [Statistical Evaluation]. M.: Statistika. 1976. 598 p.Селиванов Б.А., Беланов Е.Ф., Бормотов Н.И., Балахнин С.М., Серова О.А., Святченко В.А., Киселев Н.Н., Казачинская Е.И., Локтев В.Б., Тихонов А.Я. Производные трицикло[3.2.2.02,4]нон_8_ен_6,7_дикарбоновой кислоты высокоэффективно ингибируют репликацию различных видов ортопоксвирусов. Докл. Акад. наук. 2011; 441(3):414–8.Selivanov B.A., Belanov E.F., Bormotov N.I., Balakhin S.M., Serova O.A., Svyatchenko V.A., Kiselev N.N., Kazachinskaya E.I., Loktev V.B., Tikhonov A.Ya. [Derivatives of the tricycle[3.2.2.02,4]non-8-EN-6,7 dicarboxylic acid inhibit replication of various Orthopoxvirus species to a maximum effect]. Doklady Akademii Nauk. 2011; 441(3):414–8.Baker R.O., Bray M., Huggins J.W. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Research. 2003; 57(1-2):13–23.Baker R.O., Bray M., Huggins J.W. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Research. 2003; 57(1-2):13–23.Chen Y., Honeychurch K.M., Yang G., Byrd C.M., Harver C., Hruby D.E., Jordan R. Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol. J. 2009; 6:44.Chen Y., Honeychurch K.M., Yang G., Byrd C.M., Harver C., Hruby D.E., Jordan R. Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol. J. 2009; 6:44.Duraffour S., Andrei G., Snoeck R. Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection. IDrugs. 2010; 13(3):181–91.Duraffour S., Andrei G., Snoeck R. Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection. IDrugs. 2010; 13(3):181–91.Jordan R., Bailey T.R., Rippin S.R. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases. WO 2004/112718 A3; 2005.Jordan R., Bailey T.R., Rippin S.R. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases. WO 2004/112718 A3; 2005.Jordan R., Goff A., Frimm A., Corrado M.L., Hensley L.E., Byrd C.M., Mucker E., Shamblin J., Bolken T.C., Wlazlowski C., Johnson W., Chapman J., Twenhafel N., Tyavanagimatt S., Amantana A., Chinsangaram J., Hruby D.E., Huggins J. ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose Justification. Antimicrob. Agents Chemother. 2009; 53(5):1817–22.Jordan R., Goff A., Frimm A., Corrado M.L., Hensley L.E., Byrd C.M., Mucker E., Shamblin J., Bolken T.C., Wlazlowski C., Johnson W., Chapman J., Twenhafel N., Tyavanagimatt S., Amantana A., Chinsangaram J., Hruby D.E., Huggins J. ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose Justification. Antimicrob. Agents Chemother. 2009; 53(5):1817–22.Parker S., Touchette E., Oberle C., Almond M., Robertson A., Trost L.C., Lampert B., Painter G., Buller R.M. Efficacy of therapeutic intervention with an oral ether–lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Research. 2008; 77(1):39–49.Parker S., Touchette E., Oberle C., Almond M., Robertson A., Trost L.C., Lampert B., Painter G., Buller R.M. Efficacy of therapeutic intervention with an oral ether–lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Research. 2008; 77(1):39–49.SIGA Technologies Inc. Advisory Committee Briefing Book. Human BioArmor. Background Package for FDA Advisory Committee Meeting on December 14–15, 2011. Vol. 1. 114 р. USA; 2011 [cited 15 May 2012]. Available from: http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Antiviral Drugs AdvisoryCommittee/UCM283286.pdf.SIGA Technologies Inc. Advisory Committee Briefing Book. Human BioArmor. Background Package for FDA Advisory Committee Meeting on December 14–15, 2011. Vol. 1. 114 р. USA; 2011 [cited 15 May 2012]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM283286.pdf.Smee D.F., Sidwell R.W. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Research. 2003; 57(1–2):41–52.Smee D.F., Sidwell R.W. A review of compounds exhibiting antiorthopoxvirus activity in animal models. Antiviral Research. 2003; 57(1–2):41–52.Smith S.K., Olson V.A., Karem K.L., Jordan R., Hruby D.E., Damon I.K. In Vitro Efficacy of ST246 against Smallpox and Monkeypox. Antimicrob. Agents Chemother. 2009; 53(3):1007–12.Smith S.K., Olson V.A., Karem K.L., Jordan R., Hruby D.E., Damon I.K. In Vitro Efficacy of ST246 against Smallpox and Monkeypox. Antimicrob. Agents Chemother. 2009; 53(3):1007–12.ST-246 Completely Prevents Mortality in Symptomatic Orthopox Virus Infected Primates. SIGA Technologies, Inc. Press Release. September 26, 2007 [cited 15 May 2012]. Available from: http://investor.siga.com/releasedetail.cfm?ReleaseID=286731.ST-246 Completely Prevents Mortality in Symptomatic Orthopox Virus Infected Primates. SIGA Technologies, Inc. Press Release. September 26, 2007 [cited 15 May 2012]. Available from: http://investor.siga.com/ releasedetail.cfm?ReleaseID=286731.Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J.W., Baker R.O., Buller R.L.M., Touchette E., Waller K., Schriewer J., Neyts J., DeClercq E., Jones K., Hruby D., Jordan R. An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge. J. Virol. 2005; 79(20):13139–49.Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J.W., Baker R.O., Buller R.L.M., Touchette E., Waller K., Schriewer J., Neyts J., DeClercq E., Jones K., Hruby D., Jordan R. An Orally Bioavailable Antipoxvirus Compound (ST- 246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge. J. Virol. 2005; 79(20):13139–49.

The authors declare that there are no conflicts of interest present.